BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34215653)

  • 21. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
    Michaeli Y; Denkberg G; Sinik K; Lantzy L; Chih-Sheng C; Beauverd C; Ziv T; Romero P; Reiter Y
    J Immunol; 2009 May; 182(10):6328-41. PubMed ID: 19414786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of class Ia- and non-class Ia-restricted Chlamydia-reactive CD8+ T cell responses in humans.
    Gervassi AL; Probst P; Stamm WE; Marrazzo J; Grabstein KH; Alderson MR
    J Immunol; 2003 Oct; 171(8):4278-86. PubMed ID: 14530352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.
    Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER
    J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold.
    Valkenburg SA; Gras S; Guillonneau C; La Gruta NL; Thomas PG; Purcell AW; Rossjohn J; Doherty PC; Turner SJ; Kedzierska K
    PLoS Pathog; 2010 Aug; 6(8):e1001039. PubMed ID: 20711359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell-receptor-like antibodies - generation, function and applications.
    Dahan R; Reiter Y
    Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies.
    Cohen CJ; Sarig O; Yamano Y; Tomaru U; Jacobson S; Reiter Y
    J Immunol; 2003 Apr; 170(8):4349-61. PubMed ID: 12682272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.
    Kroll KT; Mata MM; Homan KA; Micallef V; Carpy A; Hiratsuka K; Morizane R; Moisan A; Gubler M; Walz AC; Marrer-Berger E; Lewis JA
    Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305322120. PubMed ID: 37603766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.
    Chhabra A; Yang L; Wang P; Comin-Anduix B; Das R; Chakraborty NG; Ray S; Mehrotra S; Yang H; Hardee CL; Hollis R; Dorsky DI; Koya R; Kohn DB; Ribas A; Economou JS; Baltimore D; Mukherji B
    J Immunol; 2008 Jul; 181(2):1063-70. PubMed ID: 18606658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
    Offner S; Hofmeister R; Romaniuk A; Kufer P; Baeuerle PA
    Mol Immunol; 2006 Feb; 43(6):763-71. PubMed ID: 16360021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Activation State of CD4 T Cells Alters Cellular Peptidase Activities, HIV Antigen Processing, and MHC Class I Presentation in a Sequence-Dependent Manner.
    Boucau J; Madouasse J; Kourjian G; Carlin CS; Wambua D; Berberich MJ; Le Gall S
    J Immunol; 2019 May; 202(10):2856-2872. PubMed ID: 30936293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
    Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
    J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do T cells need endogenous peptides for activation?
    Gascoigne NR
    Nat Rev Immunol; 2008 Nov; 8(11):895-900. PubMed ID: 18846098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.
    Doody AD; Kovalchin JT; Mihalyo MA; Hagymasi AT; Drake CG; Adler AJ
    J Immunol; 2004 May; 172(10):6087-92. PubMed ID: 15128793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.
    Kreiter S; Selmi A; Diken M; Sebastian M; Osterloh P; Schild H; Huber C; Türeci O; Sahin U
    J Immunol; 2008 Jan; 180(1):309-18. PubMed ID: 18097032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement.
    Stone JD; Stern LJ
    J Immunol; 2006 Feb; 176(3):1498-505. PubMed ID: 16424178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells.
    Reuben A; Godin-Ethier J; Santos MM; Lapointe R
    Mol Immunol; 2015 Jun; 65(2):259-66. PubMed ID: 25700349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens.
    Maecker HT; Ghanekar SA; Suni MA; He XS; Picker LJ; Maino VC
    J Immunol; 2001 Jun; 166(12):7268-75. PubMed ID: 11390476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.